China's Clover to supply up to 414 million COVID-19 doses to COVAX scheme | Inquirer News
Close  

China’s Clover to supply up to 414 million COVID-19 doses to COVAX scheme

/ 05:19 PM June 30, 2021
Nurse prepares to administer the AstraZeneca/Oxford vaccine against the COVID-19 at the Eka Kotebe General Hospital in Addis Ababa

A nurse prepares to administer the AstraZeneca/Oxford vaccine under the COVAX scheme against the coronavirus disease (COVID-19) at the Eka Kotebe General Hospital in Addis Ababa, Ethiopia March 13, 2021. REUTERS FILE PHOTO

BEIJING — China’s Clover Biopharmaceuticals announced on Wednesday an advance purchase agreement to supply up to 414 million doses of its COVID-19 vaccine candidate through the global vaccine sharing scheme COVAX.

The firm said it will supply an initial 64 million doses this year, pending an emergency use listing from the World Health Organization (WHO) of its vaccine candidate.

ADVERTISEMENT

The Global Alliance for Vaccines and Immunization (GAVI), which leads the COVAX scheme alongside the WHO, has options for an additional 350 million doses in 2022, Clover said.

In exchange for the supply, Clover will receive unspecified upfront payment upon positive Phase II/III trial data on its vaccine candidate.

FEATURED STORIES

The candidate entered a global large-scale trial in March and contains an effect-boosting adjuvant provided by Dynavax.

Subscribe to our daily newsletter


Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: China, Clover Biopharmaceuticals, Covax, COVID-19 Vaccines, Health
For feedback, complaints, or inquiries, contact us.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.